



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

August 31, 2017

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Proceedings of the 66th Annual General Meeting – Pfizer Limited

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed proceedings of the 66th Annual General Meeting of the Company held on August 30, 2017.

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Pfizer Limited

Prajeet Nair
Company Secretary

Encl: A/a



Fair Summary of Proceedings of the 66th Annual General Meeting of Pfizer Limited held on Wednesday, August 30, 2017 at 3.00 p.m. at Yashwantrao Chavan Pratishthan Auditorium, Next to Sachivalaya Gymkhana, General Jagannath Bhosale Marg, Mumbai-400 021.

1. The 66th Annual General Meeting (“the Meeting”) of the Members of Pfizer Limited was held on Wednesday, August 30, 2017 at 3.00 p.m. at Yashwantrao Chavan Pratishthan Auditorium, Next to Sachivalaya Gymkhana, General Jagannath Bhosale Marg, Mumbai – 400 021.
2. The meeting was attended by all Directors, Company Secretary, Chief Financial Officer, representative of Auditor, Secretarial Auditor.
3. Mr. R. A. Shah, Chairman took the Chair. The Company Secretary confirmed that the quorum was present and the Chairman commenced the proceedings of the Meeting.
4. The Chairman then introduced all the Members present on the dais and informed about proxies / representations received and registers available for inspection.
5. The Chairman then briefed the Shareholders from the Chairman’s Statement.
6. Mr. S. Sridhar, Managing Director made a presentation to the Members giving an overview of the Pharmaceutical Industry and the Company’s performance in 2016-17 and Market performance of the Company’s key brands.
7. With the consent of the Members present, the Notice convening the 66th Annual General Meeting, having been circulated to all the Members, was taken as read.
8. Since there was no qualification in the Independent Auditor’s Report, the same was not required to be read and with the permission of the Members, the Independent Auditor’s Report was taken as read.
9. The Chairman then took up the Agenda according to the Notice. He informed the Members that he and the Managing Director would be responding to the questions of the Members.
10. The Chairman stated that under the Companies Act, 2013, remote e-voting on the proposed resolutions contained in the Notice of the Meeting was mandatory and the same had been provided by the Company. Mr. Bhumitra Dholakia, Designated Partner of Dholakia & Associates LLP, had been appointed as Scrutinizer for conducting the remote e-voting and polling process in a fair and transparent manner.
11. The Chairman then put the following items on agenda for approval by poll:

Ordinary Business:

- i. To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended March 31, 2017, including the Reports of the Board of Directors and Auditors thereon.
- ii. To declare a dividend of Rs. 20.00 (200%) for the financial year ended March 31, 2017.
- iii. To appoint a Director in place of Mr. Vivek Dhariwal (DIN: 02826679) who retires by rotation and being eligible, offers himself for re-appointment.
- iv. To consider the appointment of Messrs. Walker Chandiook & Co. LLP, as Statutory Auditors of the Company for the financial year ending March 31, 2017.

Special Business:


- v. To re-appointment of Mr. Vivek Dhariwal (DIN: 02826679) as a Whole-time Director of the Company, for a period of 5 years effective May 21, 2017.
- vi. To consider the appointment of Dr. Anurita Majumdar (DIN: 05291758) as a Director of the Company, effective November 4, 2016.
- vii. To consider the appointment of Dr. Anurita Majumdar (DIN: 05291758) as a Whole-time Director of the Company, for a period of 5 years effective November 4, 2016.
- viii. To consider the appointment of Mr. Ravi Prakash Bhagavathula (DIN: 07282100) as a Director of the Company effective January 30, 2017.
- ix. To consider the appointment of Mr. Ravi Prakash Bhagavathula (DIN: 07282100) as a Whole-time Director of the Company, for a period of 5 years effective January 30, 2017.
- x. To consider and ratify the remuneration payable to Messrs. RA & Co., Cost Accountants for the financial year ending March 31, 2018.

12. The Shareholders were informed that the results of remote e-voting and poll conducted at the Meeting would be declared on or before September 1, 2017.

13. The Meeting was then concluded with a vote of thanks to the Chairman.

Thanking you,

Yours truly,
For Pfizer Limited



Prajeet Nair
Company Secretary

Place: Mumbai

Date: August 31, 2017